Objective This study aimed to assess risk factors for mother-to-child transmission (MTCT) of hepatitis B virus (HBV) after immunoprophylaxis. Methods Risk factors for MTCT were assessed using a multivariate logistic regression model. Patients We enrolled 256 mother-child pairs with positive maternal hepatitis B surface antigens (HBsAg) between January 2010 and June 2013. All children received passive-active immunization after birth. The children were tested for HBsAg at birth and 6-12 months and/or 1-3 years of age. Results Among 256 children, 10 (3.9%) developed HBV infection, all of whom were born to hepatitis B e antigen (HBeAg)-positive mothers with a high HBV DNA level (median, 7.36; range, 6.75-8.00 log10 IU/ mL). A total of 20 mothers received antiviral treatment during pregnancy. The maternal viral load decreased from an average of 7.16 to 3.08 log10 IU/mL (p<0.0001) at delivery. The multivariate logistic regression analysis showed that a high maternal HBV DNA level [odds ratio (OR) for each log10 IU/mL increase, 2.44; 95% confidence interval (CI), 1.13-5.29, p=0.023] and vaginal delivery (OR=6.96, 95% CI, 1.80-26.93, p= 0.005) were risk factors for HBV immunoprophylaxis failure. Conclusion Additional treatment strategies should be considered in HBeAg-positive mothers with an HBV DNA level above 6-7 log10 IU/mL. In addition, our study supports the use of Cesarean section for infants born to HBsAg-positive mothers.
Introduction
Globally, approximately 350-400 million individuals are infected with chronic hepatitis B (CHB), and hepatitis B virus (HBV) infection is a serious problem worldwide; approximately, 500,000 to 1.2 million people per year die from chronic hepatitis, cirrhosis and hepatocellular carcinoma (1) . HBV infection is highly endemic in China. A seroepidemiological survey conducted in 2006 showed the hepatitis B surface antigens (HBsAg) carrier rate to be 7.18% among the total population. Accordingly, there are an estimated 93 million HBV carriers and, among them, 30 million patients with CHB (2) . At present, the rate of HBV infection in Chinese patients of childbearing age reaches as high as 8.16%, and this condition consequently increases the risk of mother-to-child transmission (MTCT) of HBV (3) . In addition, the neonatal T cell function is not yet fully developed, such that newborns exhibit immune tolerance to HBsAg. As a result, it is easier for neonates to become chronic carriers once infected with HBV (4). This phenomenon makes preventing maternally transmitted HBV infection a crucial step in eradicating HBV infection.
Since an appropriate postnatal hepatitis B vaccine combined with hepatitis B immunoglobulin (HBIG) was developed to prevent MTCT in 1992 in China, the rate of HBV transmission from mother to baby has decreased by more than 90% (5) . Even so, MTCT continues to occur in some infants. A series of recent studies reported the rate of maternally transmitted HBV infection in China to range from 1.54 to 7.29% (6) (7) (8) . In order to identify risk factors related to MTCT of HBV, we conducted a retrospective study to carry out a multiple risk factor analysis by collecting clinical and epidemiological data from both mothers and children.
Materials and Methods

Subjects
This study was conducted at the West China Hospital of Sichuan University and Public Health Clinical Center of Chengdu and was approved by the Ethics Committee of West China Hospital of Sichuan University. A total of 917 children born to HBsAg-positive mothers delivered in the two hospitals between January 2010 and June 2013 were invited to join this study. The children were included in this study if they met the following inclusion criteria: (1) born to a HBsAg-positive mother, (2) received HBIG within 24 hours after birth and completed a three-dose schedule of recombinant hepatitis B vaccines at 0, 1 and 6 months, (3) documented HBV serology at birth and at least once between 6 months and 3 years of age after the completion of vaccination. Children born to mothers with co-infection with hepatitis A, C, D, E virus or human immunodeficiency virus (HIV) were excluded. Finally, a total of 278 mother-child pairs with positive maternal HBsAg met the criteria; however, 22 pairs refused to participate. As a result, 256 motherchild pairs participated in this study with parental consent.
Data collection
The data were collected via the following channels: (1) from the inpatient services at the Department of Gynecology and Obstetrics using the electronic medical record system and hospital paper charts, (2) a questionnaire designed specifically using face-to-face interviews with the mothers.
The data recorded for the mothers included maternal age at delivery, obstetric complications, maternal hepatic function, HBV serologic markers and HBV DNA level before delivery, antiviral therapy during pregnancy and maternal HBIG injection. The data for the infants paired with their mothers included sex, gestational age, birth weight, birth length, 1-min Apgar scores at birth, delivery mode, immunoprophylaxis, feeding pattern, HBV serological test results at birth and after completion of the three doses of hepatitis B vaccination. The HBsAg status of infants born to HBsAgpositive mothers at birth and at 6-12 months and/or 1-3 years of age was assessed. If a child tested HBsAg-positive at birth, HBsAg testing was repeated six months later to confirm chronic infection.
Parameters of the hepatic function, including the serum levels of total bilirubin (TB), alanine transaminase (ALT), total biliary acid (TBA) and albumin (ALB), were tested using an Automatic Biochemistry analyzer (Olympus AU5400, Olympus, Tokyo, Japan). The status of HBsAg, hepatitis B e antigen (HBeAg) and antibodies to HBeAg (anti-HBe) was determined according to a microparticle enzyme-linked immunosorbent assay (ELISA, Santa Cruz Biotech, Shanghai, China), and the serum HBV DNA level was quantified using real-time polymerase chain reaction (real-time PCR) with a linear range between 10 3 and 10 8 IU/mL (DA AN Gene, Guangzhou, China).
Statistical analysis
Group differences were examined using Student's t-test or the Wilcoxon rank-sum test for continuous variables and the Chi-square test, likelihood ratio test or Fisher's exact test for categorical variables. The HBV DNA levels were log10 transformed for the subsequent analyses. We assigned 10 3 IU/mL and 10 8 IU/mL respectively, beyond the lower limit or upper limit of quantification detection, to samples with a detectable HBV DNA level less than 10 3 IU/mL or more than 10 8 IU/mL, respectively. A univariate analysis of the risk factors associated with immunoprophylaxis failure was conducted using the chi-square test, likelihood ratio test or Fisher's exact test for categorical variables and logistic regression for continuous variables. Variables with a p value of <0.05 in the univariate analysis were included in a multivariate logistic regression analysis using the backward stepwise (Wald) method. The data analyses were performed using the Statistical Package for Social Science (SPSS) Version17.0 (SPSS, Chicago, USA). All tests were two-tailed, with the risk level set at 5% and statistical significance defined as a p value of <0.05.
Results
A total of 256 mother-child pairs with positive maternal HBsAg were included in this study. There were 172 HBeAg-positive mothers and 84 HBeAg-negative mothers. The HBeAg-positive mothers had higher HBV DNA levels at delivery than the HBeAg-negative mothers [6.96 log10 IU/ mL (interquartile range (IQR) 5.57 log10-7.50 log10) vs. 3 log10 IU/mL (IQR 3 log10-3.42 log10), p<0.0001]. Among the enrolled mothers, 20 individuals received antiviral therapy during pregnancy, while the others did not. Eighteen mothers received telbivudine treatment and two mothers received lamivudine treatment starting at 20-30 weeks of gestation. The maternal viral load decreased sharply from an average of 7.16 log10 IU/mL to less than 3.08 log10 IU/mL (p< 0.0001) at delivery.
All infants born to HBsAg-positive mothers received HBIG within 24 hours after birth and three doses of the HBV vaccine at 0, 1 and 6 months of age. All infants were tested for the HBsAg status via venipuncture immediately after birth and before the first hepatitis B vaccination. All infants underwent testing for the HBsAg status at 6-12 months of age, and 134 of them repeated HBsAg testing at 1-3 years of age. The results obtained at 1-3 years of age were consistent with those obtained at 6-12 months. Six infants were found to have both HBV DNA and HBsAg at birth and again at 6-12 months and 1-3 years of age. An additional five infants were positive for single HBsAg at birth, although three of them were negative for HBsAg and two of them were positive for both HBsAg and HBV DNA at 6-12 months and 1-3 years of age. One patient had HBV DNA only at birth and subsequently developed antigen positivity at 6 months and 1 year of age. Finally, one infant had negative findings at birth and was found to be positive for both HBsAg and HBV DNA at 1 month and 6 months of age. In brief, 10 (3.9%) infants were diagnosed HBV infection. All infected infants were born to HBeAg-positive mothers with a high HBV DNA level (median, 7.36; range, 6.75-8.00 log10 IU/mL). For the infants born to HBsAg-positive mothers with a pre-delivery HBV DNA level of <6, 6-6.99, 7-7.99 and >8 log10 IU/mL, the corresponding rate of immunoprophylaxis failure was 0%, 6.7% (3/45), 8.6% (6/70) and 7.1% (1/14), respectively. immunoprophylaxis failure (Table 3) .
Discussion
Passive-active immunoprophylaxis primarily prevents the labor and postnatal transmission of HBV; however, it plays little role in the interruption of intrauterine transmission. This study was designed to specifically assess risk factors for MTCT, which could facilitate the ability to control HBVrelated diseases. In this study, 10 (3.9%) infants were infected with HBV. All infected infants were born to HBeAgpositive mothers with a high HBV DNA level (median, 7.36; range, 6.75-8.00 log10 IU/mL).
Different from previous studies, we used the vein blood of the newborns instead of cord blood to determine the HBsAg status at birth. The vein blood was collected imme-diately after birth and before the first hepatitis B vaccination; this procedure was able to avoid contamination from maternal blood. The rate of false-positives caused by vein blood is decreased compared with that of cord blood. All infants were tested for the HBsAg status via venipuncture immediately after birth and before the first hepatitis B vaccination. Among the 10 infected children in our study, the HBVinfected status in nine infants was determined shortly after birth based on either positive HBsAg and/or HBV DNA test results obtained via venipuncture, and one infant was found to have HBV infection for the first time at 1 month of age. Furthermore, three additional infants with HBsAg positivity at birth seroreverted at 6 months of age. This finding indicates that HBsAg in vein blood is not reliable for determining the infection status in newborns. First, maternal HBsAg is unable to enter the neonatal vein blood via damaged neonatal mucosa, resulting in temporarily positive findings for HBsAg in neonatal vein blood. HBsAg are then neutralized by the subsequent administration of HBIG and hepatitis B vaccines, and the status of HBsAg may become negative. Second, the detection method is not adequately sensitive to avoid misdiagnosis. Given this background, it is very important to provide close follow-up of the serologic HBsAg and/ or HBV DNA in order to determine the HBV infection status after birth.
The present study showed that a high maternal viral load is an independent risk factor associated with MTCT. In this study, 10 HBV-infected infants were born to HBeAgpositive mothers with a high HBV DNA level, consistent with the results of previous studies (6) (7) (8) (9) (10) (11) . For example, Singh et al. (9) and Wiseman et al. (10) showed that a maternal HBV DNA level of >8 log10 copies/mL is related to immunoprophylaxis failure, while the latest study by Zou et al. (6) reported that vaccine breakthrough occurs in infants born to HBeAg-positive mothers with an HBV DNA level above 6 log10 copies/mL. The most recent study from Taiwan concluded that pregnant mothers with an HBV DNA titer above 10 7 -10 8 copies/mL should receive additional interventions to reduce the rate of immunoprophylaxis failure (11) . In the current study, among the infants born to HBsAg-positive mothers with a pre-delivery HBV DNA level of <6, 6-6.99, 7-7.99 and >8 log10 IU/mL, the corresponding rate of immunoprophylaxis failure was 0%, 6.7% (3/45), 8.6% (6/70) and 7.1% (1/14), respectively. Our findings support the recommendations of the EASL Clinical Practice Guidelines issued in 2012, which state that women with a serum HBV DNA level of >6-7 log10 IU/mL require additional treatment strategies to further reduce the rate of HBV transmission (12) .
In this study, the maternal viral load decreased sharply from an average of 7.16 log10 IU/mL to less than 3.08 log10 IU/mL at delivery following antiviral treatment (p<0.0001). None of the corresponding children were infected with HBV. Indeed, a number of studies have reported the efficacy of antiviral therapy with lamivudine, telbivudine and tenofovir during pregnancy for reducing the maternal viral load and thus transmission (13) (14) (15) (16) (17) . The significant reduction of maternal HBV DNA after antiviral therapy supports previous findings. Given our finding that a high maternal viral load is an independent risk factor associated with MTCT, antiviral therapy should be recommended for HBsAg mothers with a high serum HBV DNA titer. However, the optimal cut-off level for the maternal viral load with respect to antiviral therapy in pregnancy remains unclear and thus further studies are required to investigate the appropriate HBV DNA level at which anti-HBV therapy should be considered. In this study, there were no statistically significant differences between the antiviral group and the untreated group in terms of the decrease in the rate of MTCT. This finding is primarily attributed to the insufficient number of patients used to determine whether maternal antiviral treatment decreases the risk of MTCT. At present, the timing of administration and discontinuation of antiviral therapy, particularly potential teratogenic effects associated with antiviral agents, are unclear. Further studies to explore these issues are thus needed in the future.
In the current study, children born to HBeAg-positive mothers were more likely to be infected with HBV. All 10 infected children were born to mothers with positive findings for both HBsAg and HBeAg. These results are consistent with those of previous studies (6-8, 10, 11) . HBeAg is able to pass through the placenta from mother to fetus, resulting in T-cell tolerance in the uterus (18). Wen et al. (11) and Singh et al. (9) attributed the role of HBeAg positivity in increasing MTCT to a high maternal viral load. Our findings support this previous work, with the outcome that the HBeAg-positive mothers had significantly higher HBV viral loads than the HBeAg-negative mothers (p<0.0001).
Compared with the results of similar studies, our research shows that vaginal delivery is another risk factor associated with MTCT of HBV and that Cesarean section is superior to vaginal delivery in preventing MTCT. Lin et al. (19) discovered that Cesarean section results in the lowest rate of mother-to-fetus micro-transfusion among four delivery modes, including Cesarean section, normal spontaneous vaginal delivery, vacuum or forceps delivery and emergency Cesarean after labor. A large retrospective study of 569 HBeAg-positive mothers showed that the rate of immunoprophylaxis failure was significantly reduced by Cesarean section to 2.1% at 7-12 months after birth, compared with 5.9% associated with vaginal delivery (p<0.017) (20) . In addition, a meta-analysis of four randomized trials of 789 pregnant mothers showed that Cesarean section effectively reduces the MTCT of HBV compared to vaginal delivery (10.5 % vs. 28.0%) (21) . However, Cesarean section plays no role in reducing intrauterine infection and must be performed before the onset of labor or rupture of membranes in order to be effective (21) .
In addition, our study showed that maternal HBIG injection and feeding patterns are not related to HBV immunoprophylaxis failure. These findings are in agreement with previous results (22-25).
Our study is associated with some limitations. For example, our sample size was not very large, as some mothers refused to participate in the study and some patients did not meet the inclusion criteria. In addition, the HBV quantification assay was not sensitive, with a lower limit of detection of 10 3 IU/mL. In conclusion, a high maternal viral load and vaginal delivery increase the rate of MTCT of HBV. Additional treatment strategies are therefore needed in HBeAg-mothers with a serum HBV DNA level above 6-7 log10 IU/mL, and Cesarean section is recommended for infants born to HBsAgpositive mothers.
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